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Cardiopulmonary failureAbstract The use of ECLS in the treatment of poisoned patients has been recently reviewed by de
Lange et al. [1], but a case of aluminum phosphide poising supported by ECLS has not been
described yet.
We want to report a successful support with ECLS in a 6 year old child with severe cardiovascu-
lar failure due to aluminum phosphide poising
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Aluminum phosphide (AlP) is a commonly used pesticide
because it is cheap and very effective. But it is also one of
the most common causes of poisoning among agricultural pes-
ticides. A lethal phosphine gas liberates when it comes in con-
tact either with atmospheric moisture or with hydrochloric
acid in the stomach and no effective antidote is existing. The
mechanism of toxicity includes cellular hypoxia due to the
effect on mitochondria, inhibition of cytochrome C oxidase
and formation of highly reactive hydroxyl radicals [2–4]. The
signs and symptoms are nonspecific and instantaneous. Thetoxicity of AlP particularly affects the cardiac and vascular tis-
sues, which manifest as profound and refractory hypotension,
congestive heart failure and electrocardiographic abnormali-
ties [5,6]. The diagnosis of AlP usually depends on clinical sus-
picion or history and the management remains primarily
supportive care. Early arrival, resuscitation, diagnosis,
decrease the exposure of poison (by gastric lavage with
KMnO4, coconut oil), intensive monitoring and supportive
therapy may result in good outcome. Prompt and adequate
cardiovascular support is important and core in the manage-
ment to attain adequate tissue perfusion, oxygenation and
physiologic metabolic milieu compatible with life until the tis-
sue poison levels are reduced and spontaneous circulation is
restored. The use of IABP has been described [7,8], but not
the possibility of ECLS.
2. Case report
We admitted a 6 year old boy, (28.6 kg) from another hospital
with no tertiary care facilities for pediatrics showing rapid
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vomiting and dehydration. The whole family showed similar
symptoms, the older sister died before transferring her to our
facility and the mother was commenced on IABP.
On arrival the child was on a non-rebreather facemask
achieving Oxygen saturation of low 90’s and already on inotro-pic support with Norepinephrine 0.1 mcg/kg/min and Dobu-
tamin 5 mcg/kg/min. The blood gas showed a respiratory
compensated metabolic acidosis and the ECHO done revealed
an Ejection fraction of 15% with elevated Lactate of 5. We
intubated the patient and added additional support with Epi-
nephrine due to further hemodynamic deterioration. As con-
servative management did not show any improvement we
commenced the boy on VA ECMO via neck cannulation
(Maquet, Cardiohelp, Rotassist Set 2.8 and Qaudrox iD).
Indications for the ECMO support according to our institu-
tion were met as this is a cause of reversible cause of cardiopul-
monary failure, poor central venous Saturation with 36%, EF
of 15% despite inotropic support and rising lactate levels.
VA ECMO mode was chosen to support cardiac and pul-
monary function. 100% ECMO support in this age group iscalculated with 100 ml/kg/min = 2.8 l /min. Due to cannula
size we were only able to achieve a flow of around 1.66 l/min
which equals to 60% support. The lactate levels improved to
normal within 8 h and the central venous saturation monitored
remained above 70% shortly after the initiation of the ECMO
(picture).Due to acute kidney failure with elevated Creatine and
Urea and low urine output we as well started RRT with
CVHD via the ECMO circuit which was continued for 3 days
on ECMO support before Kidney function improved again
and CRRT could be stopped on ongoing ECMO support.
4 days after the initiation of ECMO support we phased one
episode of malignant arrhythmia (Torsade de points) which
required defibrillation and Amiodarone bolus plus continuous
infusion. This episode lasted 20 min before a junctional
rhythm could be restored and another 10 min until a sinus
rhythm was established again. During the episode perfusion
could be maintained by ECMO support.
The following days ECMO support was gradually weaned
to 30% while close monitoring Ejection fraction, end-organ
perfusion and central venous saturation (continuous monitor-
ing on ECMO machine).
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decannulate the patient from ECMO and on day 12 we were
able to extubate the young boy.
10 days later the child was discharge from the hospital. The
outcome findings on discharge were as follows
Neurologically: left sided hemiplegia, MRI showed a hem-
orrhagic infarction in the territory of the Right Middle
Cerebral artery. MRA shows no evidence of dissection,
stenosis or occlusion of the arteries which can be associated
with ECMO cannulation.
The infarction can be a result of the cardiovascular collapse
or atrial fibrillation or other cardiac pathology and symp-
toms associated with the sequelae of Aluminum phospho-
rus poisoning.
Cardiovascular: the ejection fraction improved to 70% on
day 14 after ECMO initiation and remained there until hos-
pital discharge. No antiarrhythmic medication was required
at the time of discharge; the child left the hospital with
being on Furosemide and Spironolactone.
Renal: renal parameters were in normal limits at the time of
discharge.3. Discussion
Guidelines for ECMO indications are clearly recommended by
the ELSO Community, especially for pulmonary support.
Wider use of ECLS in the sense of extended CPR becomes
more famous in the western world as well, but so far there
are very limited reports and even less recommendation of the
use of ECLS in special situation occurring in the middle east-
ern/Asian World, such as Myocarditis due to Scorpion stings,
Snake bites or supporting patients post poisoning. ARDS sec-
ondary to Malaria, Tuberculosis, Typhus, Dengue and other
newer varieties of viral pneumonias offers exciting opportuni-
ties for the applications of this life-saving modality.The recent creation of the South and West Asia Chapter of
the ELSO as well as collection of data/case reports like ours
will help the development of guidelines and recommendations
which patient do benefit from initiation of ECLS as the courses
of the initial cardiovascular or pulmonary failure are reversible
and a good outcome can be expected.
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